{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:04:32Z","timestamp":1784181872240,"version":"3.55.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>This study provides a comprehensive nationwide analysis of extensive-stage small cell lung cancer (ES-SCLC) in Hungary, examining incidence rates, demographic trends, treatment patterns, and survival outcomes. We used data from the National Health Insurance Fund (NHIF) covering the period of 2013\u20132022, and we analyzed 8,104\u00a0ES-SCLC patients who received first-line (1L) etoposide-platinum (EP) chemotherapy, all of whom were confirmed to not have received concomitant chemoradiotherapy or curative thoracic surgery and had histology results in line with SCLC. We evaluated epidemiology, regional distribution, radiotherapy use, and subsequent treatment pathways. For the efficacy analysis, we narrowed the cohort to 5,576 patients who initiated EP within 1\u00a0year of their first C34-coded lung cancer diagnosis between 2013 and 2019, enabling 3-year follow-up. Key endpoints included overall survival (OS) and progression-free survival (PFS), the latter of which was inferred using time to first subsequent therapy (TFST). Our results revealed a shifting age distribution toward the age group above 70\u00a0years, while the male-to-female ratio gradually evened out. Treatment patterns showed the increasing use of carboplatin over cisplatin and frequent short course radiotherapy. Among those who underwent subsequent therapy, EP rechallenge was most widespread. Despite high initial response rates, survival outcomes remained poor: median PFS was 6.5 months (6-month: 52.9%, 1-year: 19%, 3-year: 5.2%), and median OS was 9.3 months (6-month: 69.8%, 1-year: 37.5%, 3-year: 9.2%). These results were in line with international real-world evidence and clinical trial data. Our findings highlight the aggressive nature of ES-SCLC and provide insight to the limited efficacy of chemotherapy-based therapies, underscoring the need to improve existing 1L and subsequent-line treatments and to introduce novel options. As Hungary transitions into the immunotherapy era, future studies with extended follow-up that incorporate staging, radiotherapy intent, comorbidities, and progression data will be essential for optimizing therapeutic strategies.<\/jats:p>","DOI":"10.3389\/pore.2026.1612491","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:10:05Z","timestamp":1784178605000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Extensive-stage small cell lung cancer in Hungary: a real-world analysis (2013\u20132022)"],"prefix":"10.3389","volume":"32","author":[{"given":"Krisztina","family":"Bogos","sequence":"first","affiliation":[{"name":"National Kor\u00e1nyi Institute of Pulmonology","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Bajcsay","sequence":"additional","affiliation":[{"name":"Center of Radiotherapy, National Institute of Oncology","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"G\u00e1lffy","sequence":"additional","affiliation":[{"name":"Pulmonology Center of the Reformed Church in Hungary","place":["T\u00f6r\u00f6kb\u00e1lint, Hungary"]},{"name":"K\u00e1roli G\u00e1sp\u00e1r University of the Reformed Church in Hungary","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilla","family":"Tam\u00e1si","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"P\u00e1pai-Sz\u00e9kely","sequence":"additional","affiliation":[{"name":"Fej\u00e9r County Szent Gy\u00f6rgy University Teaching Hospital","place":["Sz\u00e9kesfeh\u00e9rv\u00e1r, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"S\u00e1rosi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of P\u00e9cs","place":["P\u00e9cs, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik\u00f3","family":"Mar\u00e1z","sequence":"additional","affiliation":[{"name":"Department of Oncotherapy, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"P\u00e1lf\u00f6ldi","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilla","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"National Kor\u00e1nyi Institute of Pulmonology","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Hoffer","sequence":"additional","affiliation":[{"name":"AstraZeneca Ltd.","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szilvia","family":"Sz\u00e9cs\u00e9nyi","sequence":"additional","affiliation":[{"name":"AstraZeneca Ltd.","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kata","family":"Kirschner","sequence":"additional","affiliation":[{"name":"AstraZeneca Ltd.","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Blasszauer","sequence":"additional","affiliation":[{"name":"MedicalScan Ltd.","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1niel","family":"Reibl","sequence":"additional","affiliation":[{"name":"MedicalScan Ltd.","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Komka","sequence":"additional","affiliation":[{"name":"MedicalScan Ltd.","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna A.","family":"Ascsill\u00e1n","sequence":"additional","affiliation":[{"name":"HCEMM-SU Translational Dermatology Research Group, Semmelweis University","place":["Budapest, Hungary"]},{"name":"Division of Infection and Immunity, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos V.","family":"Kem\u00e9ny","sequence":"additional","affiliation":[{"name":"HCEMM-SU Translational Dermatology Research Group, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyula","family":"Ostoros","sequence":"additional","affiliation":[{"name":"National Kor\u00e1nyi Institute of Pulmonology","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","unstructured":"Cancer fact sheets: lung cancer\n          \n          \n          2022"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur J Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"102306","DOI":"10.1016\/j.canep.2022.102306","article-title":"Evaluation of data quality at the Hungarian national cancer registry, 2000-2019","volume":"82","author":"Weber","year":"2023","journal-title":"Cancer Epidemiol"},{"key":"B7","volume-title":"Annual Statistical Report 2022","year":"2023"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3389\/fonc.2019.01051","article-title":"Revising incidence and mortality of lung cancer in central Europe: an epidemiology review from Hungary","volume":"9","author":"Bogos","year":"2019","journal-title":"Front Oncol"},{"key":"B9","volume-title":"Globocan 2020: Hungary Fact Sheet","year":"2021"},{"key":"B10","unstructured":"Kor\u00e1nyi bulletin\n          \n          \n          2023"},{"key":"B11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"On behalf of the ESMO guidelines committee* small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(11)60165-7","article-title":"Small-cell lung cancer","volume":"378","author":"Meerbeeck","year":"2011","journal-title":"The Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"vi99","DOI":"10.1093\/annonc\/mdt178","article-title":"Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"24","author":"Fr\u00fch","year":"2013","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e052556","DOI":"10.1136\/bmjopen-2021-052556","article-title":"Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study","volume":"13","author":"Blackhall","year":"2023","journal-title":"BMJ Open"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"The Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1612152","DOI":"10.3389\/pore.2025.1612152","article-title":"Early-stage resectable non-small cell lung cancer in Hungary","volume":"31","author":"G\u00e1lffy","year":"2025","journal-title":"Pathol Oncol Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.3390\/curroncol28040270","article-title":"Real-world treatment patterns, clinical outcomes, and health care resource utilization in extensive-stage small cell lung cancer in Canada","volume":"28","author":"O\u2019Sullivan","year":"2021","journal-title":"Curr Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2217\/fon-2022-1315","article-title":"A cross-sectional analysis of treatment patterns in small-cell lung cancer in five European countries","volume":"20","author":"Reguart","year":"2025","journal-title":"Future Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41416-025-03207-x","article-title":"Lung cancer burden attributable to ambient particulate matter: a nationally representative population-based case-control study","volume":"133","author":"Alhattab","year":"2025","journal-title":"Br J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.ccm.2012.07.001","article-title":"Occupational and environmental causes of lung cancer","volume":"33","author":"Field","year":"2012","journal-title":"Clin Chest Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1136\/bmj.38308.477650.63","article-title":"Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies","volume":"330","author":"Darby","year":"2005","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1200\/JCO.1985.3.11.1471","article-title":"VP-16 and cisplatin as first-line therapy for small-cell lung cancer","volume":"3","author":"Evans","year":"1985","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.1992.10.2.282","article-title":"Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the southeastern cancer study group","volume":"10","author":"Roth","year":"1992","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e2237699","DOI":"10.1001\/jamanetworkopen.2022.37699","article-title":"Comparison of carboplatin with cisplatin in small cell lung cancer in US veterans","volume":"5","author":"Azar","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"104618","DOI":"10.1016\/j.critrevonc.2025.104618","article-title":"Real-world evidence in extensive disease small cell lung cancer: the missing piece of the puzzle","volume":"207","author":"Damiano","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"108786","DOI":"10.1016\/j.lungcan.2025.108786","article-title":"Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer","volume":"209","author":"Andreas","year":"2025","journal-title":"Lung Cancer"},{"key":"B30","unstructured":"(II. 28.) NEFMI rendelet az eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si alapb\u00f3l a 959A\u2013L, valamint 9511\u20139515 homog\u00e9n betegs\u00e9gcsoportok szerint finansz\u00edrozott daganatellenes ter\u00e1pi\u00e1kr\u00f3l\n          \n          \n          2012"},{"key":"B31","doi-asserted-by":"publisher","first-page":"101012","DOI":"10.1016\/j.resmer.2023.101012","article-title":"Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy","volume":"84","author":"Valette","year":"2023","journal-title":"Respir Med Res"},{"key":"B32","unstructured":"EMA\n          \n          \n          2025"}],"container-title":["Pathology &amp; Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2026.1612491\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:10:07Z","timestamp":1784178607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2026.1612491\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":32,"alternative-id":["10.3389\/pore.2026.1612491"],"URL":"https:\/\/doi.org\/10.3389\/pore.2026.1612491","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"article-number":"1612491"}}